Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24890474,flow rate,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl column (4.6 × 75 mm, 3.5 µm) under isocratic conditions using acetonitrile-5 mm ammonium acetate (70:30, v/v) at a flow rate of 0.60 mL/min.","A simple, rapid and sensitive liquid chromatography-tandem mass spectrometry method for the determination of dienogest in human plasma and its pharmacokinetic applications under fasting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24890474/),[ml] / [min],0.60,1873,DB00367,Levonorgestrel
,24890474,m/,"The protonated precursor to product ion transitions monitored for dienogest and IS were at m/z 312.30 → 135.30 and 319.00 → 251.30, respectively.","A simple, rapid and sensitive liquid chromatography-tandem mass spectrometry method for the determination of dienogest in human plasma and its pharmacokinetic applications under fasting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24890474/),,312.30,1874,DB00367,Levonorgestrel
,24890474,m/,"The protonated precursor to product ion transitions monitored for dienogest and IS were at m/z 312.30 → 135.30 and 319.00 → 251.30, respectively.","A simple, rapid and sensitive liquid chromatography-tandem mass spectrometry method for the determination of dienogest in human plasma and its pharmacokinetic applications under fasting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24890474/),,319.00,1875,DB00367,Levonorgestrel
,24890474,total analysis time,The method was validated with a linearity range of 1.003-200.896 ng/mL having a total analysis time for each chromatograph of 3.0 min.,"A simple, rapid and sensitive liquid chromatography-tandem mass spectrometry method for the determination of dienogest in human plasma and its pharmacokinetic applications under fasting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24890474/),min,3.0,1876,DB00367,Levonorgestrel
>,26409262,Recovery efficiency,"Recovery efficiency at three quality control (QC) concentrations 0.5 (low), 5 (medium) and 50 (high) ng·mL(-1) was found to be >90%.",Development and validation of sensitive LC/MS/MS method for quantitative bioanalysis of levonorgestrel in rat plasma and application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26409262/),%,90,1928,DB00367,Levonorgestrel
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00367,Levonorgestrel
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00367,Levonorgestrel
,3156263,sensitivity,The sensitivity of the assay was approx 0.02 ng/ml.,A non-chromatographic radioimmunoassay for 3-oxo desogestrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3156263/),[ng] / [ml],0.02,3099,DB00367,Levonorgestrel
,3156263,peak concentrations,"The peak concentrations of 3-oxo desogestrel after a 150 micrograms dose of desogestrel in three subjects were between 0.48-0.71 ng/ml, and in two subjects 3-oxo desogestrel was still detectable 24 h after dosing.",A non-chromatographic radioimmunoassay for 3-oxo desogestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3156263/),[ng] / [ml],0.48-0.71,3100,DB00367,Levonorgestrel
,24726226,total content,"Levonorgestrel intrauterine system 13.5 mg, LNG-IUS 19.5 mg, or LNG-IUS 20 μg/24 h (total content 52 mg).",Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726226/),mg,52,3541,DB00367,Levonorgestrel
,24726226,release rate,"The in vivo LNG release rate of LNG-IUS 13.5 mg was approximately 14 μg/24 h after 24 days, declining progressively to 5 μg/24 h after 3 years.",Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726226/),[μg] / [24·h],14,3542,DB00367,Levonorgestrel
,24726226,release rate,"The in vivo LNG release rate of LNG-IUS 13.5 mg was approximately 14 μg/24 h after 24 days, declining progressively to 5 μg/24 h after 3 years.",Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726226/),[μg] / [24·h],5,3543,DB00367,Levonorgestrel
,24726226,serum concentration,"The average LNG serum concentration over 3 years of use was 74.3 ng/L, 114 ng/L, and 218 ng/L for LNG-IUS 13.5 mg, LNG-IUS 19.5 mg, and LNG-IUS 20 μg/24 h, respectively.",Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726226/),[ng] / [l],74.3,3544,DB00367,Levonorgestrel
,24726226,serum concentration,"The average LNG serum concentration over 3 years of use was 74.3 ng/L, 114 ng/L, and 218 ng/L for LNG-IUS 13.5 mg, LNG-IUS 19.5 mg, and LNG-IUS 20 μg/24 h, respectively.",Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726226/),[ng] / [l],114,3545,DB00367,Levonorgestrel
,24726226,serum concentration,"The average LNG serum concentration over 3 years of use was 74.3 ng/L, 114 ng/L, and 218 ng/L for LNG-IUS 13.5 mg, LNG-IUS 19.5 mg, and LNG-IUS 20 μg/24 h, respectively.",Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24726226/),[ng] / [l],218,3546,DB00367,Levonorgestrel
,30120779,flow rate,The flow rate was 0.8 mL/min and the injection volume was 10 μL.,Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30120779/),[ml] / [min],0.8,7486,DB00367,Levonorgestrel
,30120779,injection volume,The flow rate was 0.8 mL/min and the injection volume was 10 μL.,Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30120779/),μl,10,7487,DB00367,Levonorgestrel
,30120779,m/z,Quantitative analysis was carried out at m/z 313.0 → 108.9 and m/z 472.6 → 436.2 for LNG and IS respectively.,Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30120779/),,313.0,7488,DB00367,Levonorgestrel
,30120779,m/z,Quantitative analysis was carried out at m/z 313.0 → 108.9 and m/z 472.6 → 436.2 for LNG and IS respectively.,Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30120779/),,108.9,7489,DB00367,Levonorgestrel
,30120779,m/z,Quantitative analysis was carried out at m/z 313.0 → 108.9 and m/z 472.6 → 436.2 for LNG and IS respectively.,Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30120779/),,472.6,7490,DB00367,Levonorgestrel
,30120779,m/z,Quantitative analysis was carried out at m/z 313.0 → 108.9 and m/z 472.6 → 436.2 for LNG and IS respectively.,Quantitative determination of levonorgestrel in beagle dog plasma after vaginal administration of intravaginal ring by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30120779/),,436.2,7491,DB00367,Levonorgestrel
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,1.98,8399,DB00367,Levonorgestrel
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.73,8400,DB00367,Levonorgestrel
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],4.20,8401,DB00367,Levonorgestrel
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.96,8402,DB00367,Levonorgestrel
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,4.75,8403,DB00367,Levonorgestrel
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8404,DB00367,Levonorgestrel
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8405,DB00367,Levonorgestrel
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8406,DB00367,Levonorgestrel
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.33,8407,DB00367,Levonorgestrel
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8408,DB00367,Levonorgestrel
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.95,8409,DB00367,Levonorgestrel
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.97,8410,DB00367,Levonorgestrel
,29198449,Cmax,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[pg] / [ml],66.7,10002,DB00367,Levonorgestrel
,29198449,Cmax,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[pg] / [ml],72.7,10003,DB00367,Levonorgestrel
,29198449,AUC0-∞,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·pg] / [ml],693,10004,DB00367,Levonorgestrel
,29198449,AUC0-∞,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·pg] / [ml],740,10005,DB00367,Levonorgestrel
,29198449,Cmax,"Similarly, the mean (SD) Cmax and AUC0-∞ values of levonorgestrel were 5.0 (1.6) ng/mL and 52.2 (18.7) ng · h/mL, respectively, with the oral contraceptive alone, and 5.0 (1.6) ng/mL and 53.3 (20.4) ng · h/mL, respectively, following flibanserin; again, in both cases, the 90% CIs of the reference/test ratios were within the range of 80% to 125%, indicating that flibanserin had no significant effect on the pharmacokinetic properties of levonorgestrel.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[ng] / [ml],5.0,10006,DB00367,Levonorgestrel
,29198449,AUC0-∞,"Similarly, the mean (SD) Cmax and AUC0-∞ values of levonorgestrel were 5.0 (1.6) ng/mL and 52.2 (18.7) ng · h/mL, respectively, with the oral contraceptive alone, and 5.0 (1.6) ng/mL and 53.3 (20.4) ng · h/mL, respectively, following flibanserin; again, in both cases, the 90% CIs of the reference/test ratios were within the range of 80% to 125%, indicating that flibanserin had no significant effect on the pharmacokinetic properties of levonorgestrel.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·ng] / [ml],52.2,10007,DB00367,Levonorgestrel
,29198449,AUC0-∞,"Similarly, the mean (SD) Cmax and AUC0-∞ values of levonorgestrel were 5.0 (1.6) ng/mL and 52.2 (18.7) ng · h/mL, respectively, with the oral contraceptive alone, and 5.0 (1.6) ng/mL and 53.3 (20.4) ng · h/mL, respectively, following flibanserin; again, in both cases, the 90% CIs of the reference/test ratios were within the range of 80% to 125%, indicating that flibanserin had no significant effect on the pharmacokinetic properties of levonorgestrel.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·ng] / [ml],53.3,10008,DB00367,Levonorgestrel
,3112991,total body clearance,The total body clearance of ethinyloestradiol was significantly higher in the patients with cystic fibrosis (0.61 (SD 0.19) l/h/kg) than in control women (0.32 (0.16) l/h/kg; p less than 0.02).,Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),[l] / [h·kg],0.61,12663,DB00367,Levonorgestrel
,3112991,total body clearance,The total body clearance of ethinyloestradiol was significantly higher in the patients with cystic fibrosis (0.61 (SD 0.19) l/h/kg) than in control women (0.32 (0.16) l/h/kg; p less than 0.02).,Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),[l] / [h·kg],0.32,12664,DB00367,Levonorgestrel
,3112991,oral bioavailability,"In addition, the oral bioavailability of ethinyloestradiol was greater in women with cystic fibrosis than in controls (76.9% (11.7%) compared with 47.3% (7.5%); p less than 0.001).",Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),%,76.9,12665,DB00367,Levonorgestrel
,3112991,oral bioavailability,"In addition, the oral bioavailability of ethinyloestradiol was greater in women with cystic fibrosis than in controls (76.9% (11.7%) compared with 47.3% (7.5%); p less than 0.001).",Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),%,47.3,12666,DB00367,Levonorgestrel
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],116-160,24508,DB00367,Levonorgestrel
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],55-78,24509,DB00367,Levonorgestrel
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],30-70,24510,DB00367,Levonorgestrel
,18816505,ch,The method had a chromatographic run time of 4.5 min and linear calibration curves over the concentration ranges of 5-2000 ng/mL for mifepristone and monodemethyl-mifepristone.,Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18816505/),min,4.5,25360,DB00367,Levonorgestrel
,18816505,run time,The method had a chromatographic run time of 4.5 min and linear calibration curves over the concentration ranges of 5-2000 ng/mL for mifepristone and monodemethyl-mifepristone.,Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18816505/),min,4.5,25361,DB00367,Levonorgestrel
,18816505,recoveries,The recoveries of the method were found to be 94.5-103.7% for mifepristone and 70.7-77.3% for monodemethyl-mifepristone.,Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18816505/),%,94.5-103.7,25362,DB00367,Levonorgestrel
,18816505,recoveries,The recoveries of the method were found to be 94.5-103.7% for mifepristone and 70.7-77.3% for monodemethyl-mifepristone.,Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18816505/),%,70.7-77.3,25363,DB00367,Levonorgestrel
,26037079,C max,"After the single dose administration, the C max of EE and LNG were 44.76±18.64 pg/mL and 2.256±1.008 ng/mL, respectively.",Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037079/),[pg] / [ml],44.76,31520,DB00367,Levonorgestrel
,26037079,C max,"After the single dose administration, the C max of EE and LNG were 44.76±18.64 pg/mL and 2.256±1.008 ng/mL, respectively.",Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037079/),[ng] / [ml],2.256,31521,DB00367,Levonorgestrel
,6416745,systemic bioavailability,"The pharmacokinetic parameters of levonorgestrel in control mice showed some similarity to those observed in human subjects, save the systemic bioavailability which was about 67% in mice compared to 100% in humans.",Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416745/),%,67,36851,DB00367,Levonorgestrel
,6416745,systemic bioavailability,"The pharmacokinetic parameters of levonorgestrel in control mice showed some similarity to those observed in human subjects, save the systemic bioavailability which was about 67% in mice compared to 100% in humans.",Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416745/),%,100,36852,DB00367,Levonorgestrel
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00367,Levonorgestrel
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00367,Levonorgestrel
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00367,Levonorgestrel
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00367,Levonorgestrel
,31194965,AUClast,"LNG AUClast increased by 32.6% (312±60.9 vs. 243±82.6 ng/mL*h, p=.033, n=5) in women taking ritonavir compared to the control group (n=10).",Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [h·ml],312,38024,DB00367,Levonorgestrel
,31194965,AUClast,"LNG AUClast increased by 32.6% (312±60.9 vs. 243±82.6 ng/mL*h, p=.033, n=5) in women taking ritonavir compared to the control group (n=10).",Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [h·ml],243,38025,DB00367,Levonorgestrel
,31194965,Cmax,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],9.68,38026,DB00367,Levonorgestrel
,31194965,Cmax,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],7.62,38027,DB00367,Levonorgestrel
,31194965,Cmin,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],4.97,38028,DB00367,Levonorgestrel
,31194965,Cmin,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],3.70,38029,DB00367,Levonorgestrel
,32914172,steady-state concentration,The PK evaluation in the PK subgroups indicated that the steady-state concentration of plasma LNG after 6 months was markedly lower in the participants in the USA (geometric mean 91.2 ng/l) compared to those in Japan (263.8 ng/l).,Pearl Index study with levonorgestrel-releasing intravaginal rings: using pharmacokinetic results to investigate treatment compliance as a potential contributor for contraceptive failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914172/),[ng] / [l],91.2,42758,DB00367,Levonorgestrel
,32914172,steady-state concentration,The PK evaluation in the PK subgroups indicated that the steady-state concentration of plasma LNG after 6 months was markedly lower in the participants in the USA (geometric mean 91.2 ng/l) compared to those in Japan (263.8 ng/l).,Pearl Index study with levonorgestrel-releasing intravaginal rings: using pharmacokinetic results to investigate treatment compliance as a potential contributor for contraceptive failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914172/),[ng] / [l],263.8,42759,DB00367,Levonorgestrel
below,32914172,concentration at steady state,"In 15.7% of the samples collected in the USA and 3.5% samples in Japan, the LNG concentration at steady state was below the lower limit of quantification (10 ng/l), which is not expected with the required continuous use of the IVR documented in most of the eDiaries.",Pearl Index study with levonorgestrel-releasing intravaginal rings: using pharmacokinetic results to investigate treatment compliance as a potential contributor for contraceptive failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32914172/),ng,10,42760,DB00367,Levonorgestrel
,3133158,Half-lives,Half-lives varied from 5.6 to 25.1 hours.,Pharmacokinetic study of levonorgestrel used as a postcoital agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133158/),h,5.6 to 25.1,45907,DB00367,Levonorgestrel
,3096634,relative bioavailability (Fr),The relative bioavailability (Fr) of LNG in the tablet with respect to the solution was 107%; thus the two formulations were bioequivalent with respect to LNG.,The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096634/),%,107,49378,DB00367,Levonorgestrel
,3096634,relative bioavailability,"The relative bioavailability of EE, however, was significantly lower for the tablet (Fr 83%) compared to the solution.",The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096634/),%,83,49379,DB00367,Levonorgestrel
,3096634,Fr,"The relative bioavailability of EE, however, was significantly lower for the tablet (Fr 83%) compared to the solution.",The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096634/),%,83,49380,DB00367,Levonorgestrel
,1819548,half-life,The average half-life of E3 ranged from 1.5 to 5.3 h after the administration of E3.,Plasma estriol levels after intramuscular injection of estriol and two of its esters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1819548/),h,1.5 to 5.3,49499,DB00367,Levonorgestrel
,1819548,areas under the curve,"The average areas under the curve (in nmol.l-1.h) of E3 were between 82.5 and 161 after the administration of E3-prop or E3-hex, and between 27.1 and 37.9 when E3 had been given.",Plasma estriol levels after intramuscular injection of estriol and two of its esters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1819548/),[h·nM] / [l],82.5 and 161,49500,DB00367,Levonorgestrel
,1819548,areas under the curve,"The average areas under the curve (in nmol.l-1.h) of E3 were between 82.5 and 161 after the administration of E3-prop or E3-hex, and between 27.1 and 37.9 when E3 had been given.",Plasma estriol levels after intramuscular injection of estriol and two of its esters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1819548/),[h·nM] / [l],27.1 and 37.9,49501,DB00367,Levonorgestrel
,6820337,removal half-life (first compartment),The removal half-life (first compartment) after 90 days of exposure in 19 subjects was 16.1 (13.7-18.6) hours.,"Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6820337/),h,16.1,51038,DB00367,Levonorgestrel
,19135574,C(max),"Time concentration curves for serum LNG levels showed a mean C(max) of 7.8+/-5.5 and 8.3+/-5.7 nmol/L, a mean T(max) of 6.2+/-5.9 and 7.5+/-5.7, and comparable area under the curve for the intercourse and abstinence arm, respectively.","Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135574/),[nM] / [l],7.8,59029,DB00367,Levonorgestrel
,19135574,C(max),"Time concentration curves for serum LNG levels showed a mean C(max) of 7.8+/-5.5 and 8.3+/-5.7 nmol/L, a mean T(max) of 6.2+/-5.9 and 7.5+/-5.7, and comparable area under the curve for the intercourse and abstinence arm, respectively.","Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135574/),[nM] / [l],8.3,59030,DB00367,Levonorgestrel
,19135574,T(max),"Time concentration curves for serum LNG levels showed a mean C(max) of 7.8+/-5.5 and 8.3+/-5.7 nmol/L, a mean T(max) of 6.2+/-5.9 and 7.5+/-5.7, and comparable area under the curve for the intercourse and abstinence arm, respectively.","Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135574/),,6.2,59031,DB00367,Levonorgestrel
,19135574,T(max),"Time concentration curves for serum LNG levels showed a mean C(max) of 7.8+/-5.5 and 8.3+/-5.7 nmol/L, a mean T(max) of 6.2+/-5.9 and 7.5+/-5.7, and comparable area under the curve for the intercourse and abstinence arm, respectively.","Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135574/),,7.5,59032,DB00367,Levonorgestrel
,29579732,flow rate,"The mobile phases consisted of de-ionized water plus 0.1% NH4OH (100:0.1%, v/v) (A), and methanol plus 0.1% NH4OH (100:0.1%, v/v) (B) delivered as a gradient at a flow rate of 400 μL/min.","Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29579732/),[μl] / [min],400,63773,DB00367,Levonorgestrel
,8143453,initial rate,"The pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel (L-NOG) at an initial rate of 27 micrograms/24 h were studied in a group of 12 normally menstruating women during 90 days of continuous use (i.e., during three 30-day treatment segments).",Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 micrograms/24 hours: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8143453/),[μg] / [24·h],27,64085,DB00367,Levonorgestrel
,22299599,clearance,"Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05).",Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22299599/),[l] / [h],63.3,64136,DB00367,Levonorgestrel
,22299599,clearance,"Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05).",Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22299599/),[l] / [h],53.9,64137,DB00367,Levonorgestrel
,2496951,peak level,"A peak level of 16 nmol/l was reached after 2 hours, T 1/2 was estimated to be 14.5 hours (8.5-18.5) in the 24-48-hour interval after dosing.",The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496951/),[nM] / [l],16,68175,DB00367,Levonorgestrel
,2496951,T 1/2,"A peak level of 16 nmol/l was reached after 2 hours, T 1/2 was estimated to be 14.5 hours (8.5-18.5) in the 24-48-hour interval after dosing.",The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496951/),h,14.5,68176,DB00367,Levonorgestrel
,6786829,peak,Plasma concentrations of Ng rise to a peak of 3.6 ng/ml after an oral dose of 150 microgram and to 5.0 ng/ml after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[ng] / [ml],3.6,71125,DB00367,Levonorgestrel
,6786829,peak,Plasma concentrations of Ng rise to a peak of 3.6 ng/ml after an oral dose of 150 microgram and to 5.0 ng/ml after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[ng] / [ml],5.0,71126,DB00367,Levonorgestrel
,6786829,half-lives,"Following the intravenous administration of Ng, plasma concentrations of the steroid decline bi-exponentially with mean half-lives of 0.76 and 11.55 hours.",The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),h,0.76,71127,DB00367,Levonorgestrel
,6786829,half-lives,"Following the intravenous administration of Ng, plasma concentrations of the steroid decline bi-exponentially with mean half-lives of 0.76 and 11.55 hours.",The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),h,11.55,71128,DB00367,Levonorgestrel
,6786829,systemic bioavailability,Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),%,89,71129,DB00367,Levonorgestrel
,6786829,systemic bioavailability,Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),%,99,71130,DB00367,Levonorgestrel
,6786829,peak values,The peak values after oral dosing were 103 pg/ml and were reached by 1.0 hour in all subjects.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[pg] / [ml],103,71131,DB00367,Levonorgestrel
,12042264,Maximum LNG concentrations,"Maximum LNG concentrations were of approximately 27 nmol/l for treatments A and B, and close to 40 nmol/l for treatment C.",Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12042264/),[nM] / [l],27,82430,DB00367,Levonorgestrel
,12042264,Maximum LNG concentrations,"Maximum LNG concentrations were of approximately 27 nmol/l for treatments A and B, and close to 40 nmol/l for treatment C.",Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12042264/),[nM] / [l],40,82431,DB00367,Levonorgestrel
,1802819,terminal half-life,"This increase was due to an increased dose of LNG according to the triphasic dose regimen, a concomitantly ethinylestradiol-induced increase in SHBG and due to pharmacokinetic accumulation, since LNG had a terminal half-life of approximately 28.5 h and the dosing interval was 24 h.",Pharmacokinetics of levonorgestrel in 18 women after 1 month of treatment with a triphasic oral contraceptive. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802819/),h,28.5,83453,DB00367,Levonorgestrel
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB00367,Levonorgestrel
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB00367,Levonorgestrel
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB00367,Levonorgestrel
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.3,94875,DB00367,Levonorgestrel
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.7,94876,DB00367,Levonorgestrel
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,29.6,94877,DB00367,Levonorgestrel
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],59.3,94878,DB00367,Levonorgestrel
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],58.2,94879,DB00367,Levonorgestrel
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],55.8,94880,DB00367,Levonorgestrel
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,30.6,94881,DB00367,Levonorgestrel
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,31.2,94882,DB00367,Levonorgestrel
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],46.6,94883,DB00367,Levonorgestrel
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],45.6,94884,DB00367,Levonorgestrel
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,11.4,94885,DB00367,Levonorgestrel
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,12.4,94886,DB00367,Levonorgestrel
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,13.5,94887,DB00367,Levonorgestrel
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],323,94888,DB00367,Levonorgestrel
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],530,94889,DB00367,Levonorgestrel
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],459,94890,DB00367,Levonorgestrel
,15722070,Cmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],5.4,97600,DB00367,Levonorgestrel
,15722070,Cmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],14.6,97601,DB00367,Levonorgestrel
,15722070,Tmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,5.9,97602,DB00367,Levonorgestrel
,15722070,Tmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,2.0,97603,DB00367,Levonorgestrel
,15722070,Relative bioavailabilities,"Relative bioavailabilities for levonorgestrel and ethinyl estradiol were 58% and 175%, respectively.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),%,58,97604,DB00367,Levonorgestrel
,15722070,Relative bioavailabilities,"Relative bioavailabilities for levonorgestrel and ethinyl estradiol were 58% and 175%, respectively.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),%,175,97605,DB00367,Levonorgestrel
,15722070,Cmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],5.4,97606,DB00367,Levonorgestrel
,15722070,Cmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],15.2,97607,DB00367,Levonorgestrel
,15722070,Tmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,7.4,97608,DB00367,Levonorgestrel
,15722070,Tmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,1.3,97609,DB00367,Levonorgestrel
,15722070,relative bioavailability,The relative bioavailability was 62%.,Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),%,62,97610,DB00367,Levonorgestrel
,17519152,maximum concentrations (Cmax),"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),[nM] / [l],14.1,97960,DB00367,Levonorgestrel
,17519152,maximum concentrations (Cmax),"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),[nM] / [l],11.7,97961,DB00367,Levonorgestrel
,17519152,Tmax,"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),h,12.0,97962,DB00367,Levonorgestrel
,17519152,Tmax,"Serum LNG maximum concentrations (Cmax) were 14.1+/-2.1 and 11.7+/-2.7 nmol/L and Tmax was 12.0 and 6.0 h for the low and high dose, respectively, with large intersubject variability within the first 48 h.","Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for ""dual protection"" contraception. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519152/),h,6.0,97963,DB00367,Levonorgestrel
,16083195,peak (,"The results found that the mean peak (X +/- SD) serum concentration (Cmax) of the Thai-made pill and Hungarian-pill were 1.18 +/- 0.12 and 1.14 +/- 0.10 ng/ml, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),[ng] / [ml],1.18,99936,DB00367,Levonorgestrel
,16083195,peak (,"The results found that the mean peak (X +/- SD) serum concentration (Cmax) of the Thai-made pill and Hungarian-pill were 1.18 +/- 0.12 and 1.14 +/- 0.10 ng/ml, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),[ng] / [ml],1.14,99937,DB00367,Levonorgestrel
,16083195,serum concentration (Cmax),"The results found that the mean peak (X +/- SD) serum concentration (Cmax) of the Thai-made pill and Hungarian-pill were 1.18 +/- 0.12 and 1.14 +/- 0.10 ng/ml, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),[ng] / [ml],1.18,99938,DB00367,Levonorgestrel
,16083195,serum concentration (Cmax),"The results found that the mean peak (X +/- SD) serum concentration (Cmax) of the Thai-made pill and Hungarian-pill were 1.18 +/- 0.12 and 1.14 +/- 0.10 ng/ml, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),[ng] / [ml],1.14,99939,DB00367,Levonorgestrel
,16083195,time to peak serum concentration (Tmax),"The time to peak serum concentration (Tmax) of the Thai-made pill and Hungarian-pill were 1.56 +/- 0.73 and 1.58 +/- 0.67 hrs, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),h,1.56,99940,DB00367,Levonorgestrel
,16083195,time to peak serum concentration (Tmax),"The time to peak serum concentration (Tmax) of the Thai-made pill and Hungarian-pill were 1.56 +/- 0.73 and 1.58 +/- 0.67 hrs, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),h,1.58,99941,DB00367,Levonorgestrel
,16083195,area under the curve (AUC),"The mean area under the curve (AUC) of Thai-made pill and Hungarian-pill were 2.14 +/- 0.21 and 2.09 +/- 0.16 ng.h/ml, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),[h·ng] / [ml],2.14,99942,DB00367,Levonorgestrel
,16083195,area under the curve (AUC),"The mean area under the curve (AUC) of Thai-made pill and Hungarian-pill were 2.14 +/- 0.21 and 2.09 +/- 0.16 ng.h/ml, respectively.",Bioequivalence study of postcoital emergency contraceptions containing levonorgestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16083195/),[h·ng] / [ml],2.09,99943,DB00367,Levonorgestrel
,11245553,terminal half-lives,"Serum concentrations ofdrospirenone declined, with mean terminal half-lives of 30.8-32.5 h.",A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245553/),h,30.8-32.5,100703,DB00367,Levonorgestrel
,11245553,accumulation ratio,"Accumulation of both drospirenone and ethinylestradiol was observed within a treatment cycle, with a mean accumulation ratio of 3.0 for drospirenone and 2.1 for ethinylestradiol.",A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245553/),,3.0,100704,DB00367,Levonorgestrel
,11245553,accumulation ratio,"Accumulation of both drospirenone and ethinylestradiol was observed within a treatment cycle, with a mean accumulation ratio of 3.0 for drospirenone and 2.1 for ethinylestradiol.",A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245553/),,2.1,100705,DB00367,Levonorgestrel
,3937664,release rate,The pharmacokinetic and pharmacodynamic effects of a new type of levonorgestrel-releasing vaginal device (with an in vitro release rate of 25 micrograms/24 h) were studied in a group of 18 normally menstruating women during a period of 90 days of continuous use.,A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937664/),[μg] / [24·h],25,101141,DB00367,Levonorgestrel
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,7.7,102678,DB00367,Levonorgestrel
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,7.0,102679,DB00367,Levonorgestrel
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,37.1,102680,DB00367,Levonorgestrel
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,33.1,102681,DB00367,Levonorgestrel
,1458891,maximum concentrations,"After single dose administration, maximum concentrations of LNG in the serum were 4.3 +/- 1.3 ng/ml.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),[ng] / [ml],4.3,105232,DB00367,Levonorgestrel
,1458891,half-lives,"Post maximum drug levels declined biphasically with half-lives of 0.6 +/- 0.2 h and 13.9 +/- 3.2 h, respectively.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),h,0.6,105233,DB00367,Levonorgestrel
,1458891,half-lives,"Post maximum drug levels declined biphasically with half-lives of 0.6 +/- 0.2 h and 13.9 +/- 3.2 h, respectively.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),h,13.9,105234,DB00367,Levonorgestrel
,1458891,clearance,The clearance was calculated to be 1.5 +/- 0.6 ml x min-1 x kg-1.,"Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),[ml] / [kg·min],1.5,105235,DB00367,Levonorgestrel
,1458891,free fraction,"The free fraction of LNG was 1.1 +/- 0.1% and the fractions bound to SHBG and albumin were 61.8 +/- 6.7% and 37.1 +/- 6.7%, respectively.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),%,1.1,105236,DB00367,Levonorgestrel
,1458891,fractions bound,"The free fraction of LNG was 1.1 +/- 0.1% and the fractions bound to SHBG and albumin were 61.8 +/- 6.7% and 37.1 +/- 6.7%, respectively.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),%,61.8,105237,DB00367,Levonorgestrel
,1458891,fractions bound,"The free fraction of LNG was 1.1 +/- 0.1% and the fractions bound to SHBG and albumin were 61.8 +/- 6.7% and 37.1 +/- 6.7%, respectively.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),%,37.1,105238,DB00367,Levonorgestrel
,1458891,serum trough levels,"There was a gradual decrease in serum trough levels of LNG from about 0.5 to 0.3 ng/ml during the cycle, and a concomitant decrease in SHBG concentrations in the serum by about 50%.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),[ng] / [ml],0.5,105239,DB00367,Levonorgestrel
,1458891,serum trough levels,"There was a gradual decrease in serum trough levels of LNG from about 0.5 to 0.3 ng/ml during the cycle, and a concomitant decrease in SHBG concentrations in the serum by about 50%.","Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),[ng] / [ml],0.3,105240,DB00367,Levonorgestrel
,1458891,Total serum clearance,Total serum clearance increased during the same time period from a mean value of 1.5 to about 2.5 ml x min-1 x kg-1.,"Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),[ml] / [kg·min],1.5,105241,DB00367,Levonorgestrel
,1458891,Total serum clearance,Total serum clearance increased during the same time period from a mean value of 1.5 to about 2.5 ml x min-1 x kg-1.,"Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458891/),[ml] / [kg·min],2.5,105242,DB00367,Levonorgestrel
,23153898,clearance,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),[l] / [h],0.52,111704,DB00367,Levonorgestrel
,23153898,half-life,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),h,65,111705,DB00367,Levonorgestrel
,23153898,area under the curve (AUC),"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),[h·ng] / [ml],232,111706,DB00367,Levonorgestrel
,23153898,time to reach steady state,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),d,13.6,111707,DB00367,Levonorgestrel
,28126541,AUC0-24,"After LNG-EC, mean AUC0-24 and maximum concentration (Cmax) were 50% lower among obese-BMI women than among normal-BMI women (AUC0-24 100.8 vs. 208.5ng*h/mL, IQRobese-BMI 35.8, IQRnormal-BMI 74.2, p≤.01; Cmax 10.8 vs. 18.2ng/mL, p=.01).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[h·ng] / [ml],100.8,113813,DB00367,Levonorgestrel
,28126541,AUC0-24,"After LNG-EC, mean AUC0-24 and maximum concentration (Cmax) were 50% lower among obese-BMI women than among normal-BMI women (AUC0-24 100.8 vs. 208.5ng*h/mL, IQRobese-BMI 35.8, IQRnormal-BMI 74.2, p≤.01; Cmax 10.8 vs. 18.2ng/mL, p=.01).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[h·ng] / [ml],208.5,113814,DB00367,Levonorgestrel
,28126541,Cmax,"After LNG-EC, mean AUC0-24 and maximum concentration (Cmax) were 50% lower among obese-BMI women than among normal-BMI women (AUC0-24 100.8 vs. 208.5ng*h/mL, IQRobese-BMI 35.8, IQRnormal-BMI 74.2, p≤.01; Cmax 10.8 vs. 18.2ng/mL, p=.01).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[ng] / [ml],10.8,113815,DB00367,Levonorgestrel
,28126541,Cmax,"After LNG-EC, mean AUC0-24 and maximum concentration (Cmax) were 50% lower among obese-BMI women than among normal-BMI women (AUC0-24 100.8 vs. 208.5ng*h/mL, IQRobese-BMI 35.8, IQRnormal-BMI 74.2, p≤.01; Cmax 10.8 vs. 18.2ng/mL, p=.01).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[ng] / [ml],18.2,113816,DB00367,Levonorgestrel
,28126541,AUC0-24,"After UPA-EC, AUC0-24 and Cmax were similar between obese-BMI and normal-BMI women (AUC0-24 362.5 vs. 293.5ng*h/mL, IQRobese-BMI 263.2, IQRnormal-BMI 112.5, p=.15; Cmax 95.6 vs. 89.3ng/mL, p=.70).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[h·ng] / [ml],362.5,113817,DB00367,Levonorgestrel
,28126541,AUC0-24,"After UPA-EC, AUC0-24 and Cmax were similar between obese-BMI and normal-BMI women (AUC0-24 362.5 vs. 293.5ng*h/mL, IQRobese-BMI 263.2, IQRnormal-BMI 112.5, p=.15; Cmax 95.6 vs. 89.3ng/mL, p=.70).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[h·ng] / [ml],293.5,113818,DB00367,Levonorgestrel
,28126541,Cmax,"After UPA-EC, AUC0-24 and Cmax were similar between obese-BMI and normal-BMI women (AUC0-24 362.5 vs. 293.5ng*h/mL, IQRobese-BMI 263.2, IQRnormal-BMI 112.5, p=.15; Cmax 95.6 vs. 89.3ng/mL, p=.70).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[ng] / [ml],95.6,113819,DB00367,Levonorgestrel
,28126541,Cmax,"After UPA-EC, AUC0-24 and Cmax were similar between obese-BMI and normal-BMI women (AUC0-24 362.5 vs. 293.5ng*h/mL, IQRobese-BMI 263.2, IQRnormal-BMI 112.5, p=.15; Cmax 95.6 vs. 89.3ng/mL, p=.70).",Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28126541/),[ng] / [ml],89.3,113820,DB00367,Levonorgestrel
,7705098,terminal half-life,"Following single dose administration, a mean terminal half-life of 22 h was observed for LNG.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),h,22,115032,DB00367,Levonorgestrel
,7705098,total clearance,The total clearance was 1.0 ml x min-1 x kg-1 and the volume of distribution was 128 l.,Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],1.0,115033,DB00367,Levonorgestrel
,7705098,volume of distribution,The total clearance was 1.0 ml x min-1 x kg-1 and the volume of distribution was 128 l.,Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),l,128,115034,DB00367,Levonorgestrel
,7705098,total,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],0.5,115035,DB00367,Levonorgestrel
,7705098,free clearance,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],50,115036,DB00367,Levonorgestrel
,7705098,volume of distribution,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),l,52,115037,DB00367,Levonorgestrel
,7705098,free fraction,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,1.4,115038,DB00367,Levonorgestrel
,7705098,fractions bound,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,55.0,115039,DB00367,Levonorgestrel
,7705098,fractions bound,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,43.6,115040,DB00367,Levonorgestrel
,7705098,free fraction,"At the end of cycle one, the free fraction was only 1.0% and the fractions bound to SHBG and albumin were 69.4% and 30.0%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,1.0,115041,DB00367,Levonorgestrel
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],331.2,115042,DB00367,Levonorgestrel
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],369.6,115043,DB00367,Levonorgestrel
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],298.3,115044,DB00367,Levonorgestrel
,25961260,steady-state plasma concentrations (Css,"In Study 1, mean steady-state plasma concentrations (Css, pg/mL) for the TCDS were 17 pg/mL to 26 pg/mL for EE and 1117 pg/mL to 1505 pg/mL for LNG (for AG200LE and AG200-12.5 respectively).","Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25961260/),[pg] / [ml],17,117367,DB00367,Levonorgestrel
,25961260,steady-state plasma concentrations (Css,"In Study 1, mean steady-state plasma concentrations (Css, pg/mL) for the TCDS were 17 pg/mL to 26 pg/mL for EE and 1117 pg/mL to 1505 pg/mL for LNG (for AG200LE and AG200-12.5 respectively).","Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25961260/),[pg] / [ml],26,117368,DB00367,Levonorgestrel
,25961260,steady-state plasma concentrations (Css,"In Study 1, mean steady-state plasma concentrations (Css, pg/mL) for the TCDS were 17 pg/mL to 26 pg/mL for EE and 1117 pg/mL to 1505 pg/mL for LNG (for AG200LE and AG200-12.5 respectively).","Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25961260/),[pg] / [ml],1117,117369,DB00367,Levonorgestrel
,25961260,steady-state plasma concentrations (Css,"In Study 1, mean steady-state plasma concentrations (Css, pg/mL) for the TCDS were 17 pg/mL to 26 pg/mL for EE and 1117 pg/mL to 1505 pg/mL for LNG (for AG200LE and AG200-12.5 respectively).","Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25961260/),[pg] / [ml],1505,117370,DB00367,Levonorgestrel
,2105872,peak levels,The serum concentration-time profiles for the three formulations showed that the range of mean peak levels was 2.3-2.8 ng/ml for LNG and 116-159 pg/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[ng] / [ml],2.3-2.8,119744,DB00367,Levonorgestrel
,2105872,peak levels,The serum concentration-time profiles for the three formulations showed that the range of mean peak levels was 2.3-2.8 ng/ml for LNG and 116-159 pg/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[pg] / [ml],116-159,119745,DB00367,Levonorgestrel
,2105872,areas under the curves,The ranges of mean values calculated for the areas under the curves were 15-16 ng.hr/ml for LNG and 1053-1390 pg.hr/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[h·ng] / [ml],15-16,119746,DB00367,Levonorgestrel
,2105872,areas under the curves,The ranges of mean values calculated for the areas under the curves were 15-16 ng.hr/ml for LNG and 1053-1390 pg.hr/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[h·pg] / [ml],1053-1390,119747,DB00367,Levonorgestrel
,2105872,volume of distribution,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[l] / [kg],1.6-1.8,119748,DB00367,Levonorgestrel
,2105872,volume of distribution,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[l] / [kg],7.7-9.1,119749,DB00367,Levonorgestrel
,2105872,clearance,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[ml] / [h·kg],84-88,119750,DB00367,Levonorgestrel
,2105872,clearance,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[ml] / [h·kg],0.67-0.99,119751,DB00367,Levonorgestrel
,2105872,half-life,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),h,13-15,119752,DB00367,Levonorgestrel
,2105872,half-life,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),h,7-12,119753,DB00367,Levonorgestrel
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,15.5,128388,DB00367,Levonorgestrel
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,14.1,128389,DB00367,Levonorgestrel
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],488,128390,DB00367,Levonorgestrel
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],470,128391,DB00367,Levonorgestrel
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.8,128392,DB00367,Levonorgestrel
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.1,128393,DB00367,Levonorgestrel
,9186253,half-life,"No difference in pharmacokinetic parameters between VGB and placebo sessions were found for ethinyl estradiol (half-life, 12.5 +/- 3.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,12.5,128394,DB00367,Levonorgestrel
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],874,128395,DB00367,Levonorgestrel
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],939,128396,DB00367,Levonorgestrel
,9186253,half-life,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,17.7,128397,DB00367,Levonorgestrel
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],27.5,128398,DB00367,Levonorgestrel
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],30.0,128399,DB00367,Levonorgestrel
,15198534,Percentage relative bioavailability (F*),"Percentage relative bioavailability (F*) of 97.6%, 98.6%, and 109.9% were observed after pulmonary administration of plain drug formulation (LP1), physical mixture (plain drug along with constituents of liposomes [LP2]), and liposomal (LP3) formulations of the drug, respectively.",Pulmonary absorption of liposomal levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),%,97.6,128935,DB00367,Levonorgestrel
,15198534,Percentage relative bioavailability (F*),"Percentage relative bioavailability (F*) of 97.6%, 98.6%, and 109.9% were observed after pulmonary administration of plain drug formulation (LP1), physical mixture (plain drug along with constituents of liposomes [LP2]), and liposomal (LP3) formulations of the drug, respectively.",Pulmonary absorption of liposomal levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),%,98.6,128936,DB00367,Levonorgestrel
,15198534,Percentage relative bioavailability (F*),"Percentage relative bioavailability (F*) of 97.6%, 98.6%, and 109.9% were observed after pulmonary administration of plain drug formulation (LP1), physical mixture (plain drug along with constituents of liposomes [LP2]), and liposomal (LP3) formulations of the drug, respectively.",Pulmonary absorption of liposomal levonorgestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),%,109.9,128937,DB00367,Levonorgestrel
,15198534,Cmax,"Following oral administration, Cmax of 14.4 +/- 0.6 ng/mL was observed at 2.1 +/- 0.2 hours followed by subtherapeutic concentration beyond 30 +/- 0.2 hours, while after pulmonary administration of LP1, LP2, and LP3 formulations, Cmax of 4.4 +/- 0.4 ng/mL, 4.2 +/- 0.5 ng/mL, and 4.4 +/- 0.6 ng/mL were observed at 6.0 +/- 0.2 hours, 7.0 +/- 0.2 hours, and 6.8 +/- 0.2 hours, respectively, followed by maintenance of effective plasma drug concentration up to 60 +/- 2 hours.",Pulmonary absorption of liposomal levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),[ng] / [ml],14.4,128938,DB00367,Levonorgestrel
,15198534,Cmax,"Following oral administration, Cmax of 14.4 +/- 0.6 ng/mL was observed at 2.1 +/- 0.2 hours followed by subtherapeutic concentration beyond 30 +/- 0.2 hours, while after pulmonary administration of LP1, LP2, and LP3 formulations, Cmax of 4.4 +/- 0.4 ng/mL, 4.2 +/- 0.5 ng/mL, and 4.4 +/- 0.6 ng/mL were observed at 6.0 +/- 0.2 hours, 7.0 +/- 0.2 hours, and 6.8 +/- 0.2 hours, respectively, followed by maintenance of effective plasma drug concentration up to 60 +/- 2 hours.",Pulmonary absorption of liposomal levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),[ng] / [ml],4.4,128939,DB00367,Levonorgestrel
,15198534,Cmax,"Following oral administration, Cmax of 14.4 +/- 0.6 ng/mL was observed at 2.1 +/- 0.2 hours followed by subtherapeutic concentration beyond 30 +/- 0.2 hours, while after pulmonary administration of LP1, LP2, and LP3 formulations, Cmax of 4.4 +/- 0.4 ng/mL, 4.2 +/- 0.5 ng/mL, and 4.4 +/- 0.6 ng/mL were observed at 6.0 +/- 0.2 hours, 7.0 +/- 0.2 hours, and 6.8 +/- 0.2 hours, respectively, followed by maintenance of effective plasma drug concentration up to 60 +/- 2 hours.",Pulmonary absorption of liposomal levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),[ng] / [ml],4.2,128940,DB00367,Levonorgestrel
,15198534,Cmax,"Following oral administration, Cmax of 14.4 +/- 0.6 ng/mL was observed at 2.1 +/- 0.2 hours followed by subtherapeutic concentration beyond 30 +/- 0.2 hours, while after pulmonary administration of LP1, LP2, and LP3 formulations, Cmax of 4.4 +/- 0.4 ng/mL, 4.2 +/- 0.5 ng/mL, and 4.4 +/- 0.6 ng/mL were observed at 6.0 +/- 0.2 hours, 7.0 +/- 0.2 hours, and 6.8 +/- 0.2 hours, respectively, followed by maintenance of effective plasma drug concentration up to 60 +/- 2 hours.",Pulmonary absorption of liposomal levonorgestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198534/),[ng] / [ml],4.4,128941,DB00367,Levonorgestrel
,15019826,Relative bioavailabilities,"Relative bioavailabilities of 29.93%, 32.14%, and 25.97% were observed after nasal administration of plain drug, physical mixture, and liposomal formulations, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,29.93,129176,DB00367,Levonorgestrel
,15019826,Relative bioavailabilities,"Relative bioavailabilities of 29.93%, 32.14%, and 25.97% were observed after nasal administration of plain drug, physical mixture, and liposomal formulations, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,32.14,129177,DB00367,Levonorgestrel
,15019826,Relative bioavailabilities,"Relative bioavailabilities of 29.93%, 32.14%, and 25.97% were observed after nasal administration of plain drug, physical mixture, and liposomal formulations, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,25.97,129178,DB00367,Levonorgestrel
,15019826,Bioavailability,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,29.93,129179,DB00367,Levonorgestrel
,15019826,Bioavailability,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,101.70,129180,DB00367,Levonorgestrel
,15019826,Bioavailability,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,99.42,129181,DB00367,Levonorgestrel
,15019826,Bioavailability,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),%,0.5,129182,DB00367,Levonorgestrel
,15019826,plasma half life,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),h,7.0,129183,DB00367,Levonorgestrel
,15019826,plasma half life,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),h,55.7,129184,DB00367,Levonorgestrel
,15019826,plasma half life,"Bioavailability was improved from 29.93% to 101.70% and 99.42%, respectively, for chitosan (0.5%) and carbopol 934p (0.5%) formulations, with a significantly improved plasma half life from 7.0 hours to 55.7 hours and 52.9 hours, respectively.",Nasal delivery of levonorgestrel for contraception: an experimental study in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019826/),h,52.9,129185,DB00367,Levonorgestrel
,27390369,plasma concentrations,"At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period.","Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390369/),[μg] / [l],0.228,130065,DB00367,Levonorgestrel
,27390369,plasma concentrations,"At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period.","Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390369/),[μg] / [l],12.5,130066,DB00367,Levonorgestrel
,27390369,plasma concentrations,"At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period.","Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390369/),[μg] / [l],0.269,130067,DB00367,Levonorgestrel
,27390369,plasma concentrations,"At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period.","Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390369/),[μg] / [l],19.8,130068,DB00367,Levonorgestrel
,27390369,plasma concentrations,"At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period.","Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390369/),[μg] / [l],0.384,130069,DB00367,Levonorgestrel
,27390369,plasma concentrations,"At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period.","Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27390369/),[μg] / [l],37.3,130070,DB00367,Levonorgestrel
,29403945,run time,A run time of 9.0 min for each sample made it possible to analyze a throughput of more than 100 samples per day.,High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403945/),min,9.0,132759,DB00367,Levonorgestrel
,21692601,t(max),"Ethinyl oestradiol absorption was rapid (median t(max) approximately 1 hour), and was not affected by ticagrelor.",Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692601/),h,1,133521,DB00367,Levonorgestrel
≥,29679590,trough serum LNG concentrations,We evaluated pharmacokinetics via the weekly trough serum LNG concentrations (≥180 pg/mL considered therapeutic).,Phase I/II pharmacokinetic and pharmacodynamic evaluation of two levonorgestrel-only contraceptive patches in a multicenter randomized trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679590/),[pg] / [ml],180,134656,DB00367,Levonorgestrel
,7985513,Peak plasma LNG level,"Peak plasma LNG level of 67.66 nmol.L-1 was obtained 4.88 h after im of LNG microcrystals, T1/2 = 5.78 d, MRT = 10.16 d and T < 0.32 nmol.L-1 = 41.50 d.",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],67.66,134725,DB00367,Levonorgestrel
,7985513,T1/2,"Peak plasma LNG level of 67.66 nmol.L-1 was obtained 4.88 h after im of LNG microcrystals, T1/2 = 5.78 d, MRT = 10.16 d and T < 0.32 nmol.L-1 = 41.50 d.",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,5.78,134726,DB00367,Levonorgestrel
,7985513,MRT,"Peak plasma LNG level of 67.66 nmol.L-1 was obtained 4.88 h after im of LNG microcrystals, T1/2 = 5.78 d, MRT = 10.16 d and T < 0.32 nmol.L-1 = 41.50 d.",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,10.16,134727,DB00367,Levonorgestrel
<,7985513,T,"Peak plasma LNG level of 67.66 nmol.L-1 was obtained 4.88 h after im of LNG microcrystals, T1/2 = 5.78 d, MRT = 10.16 d and T < 0.32 nmol.L-1 = 41.50 d.",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],0.32,134728,DB00367,Levonorgestrel
,7985513,T,"Peak plasma LNG level of 67.66 nmol.L-1 was obtained 4.88 h after im of LNG microcrystals, T1/2 = 5.78 d, MRT = 10.16 d and T < 0.32 nmol.L-1 = 41.50 d.",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,41.50,134729,DB00367,Levonorgestrel
,7985513,Cmax1,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],15.19,134730,DB00367,Levonorgestrel
,7985513,Cmax1,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],33.61,134731,DB00367,Levonorgestrel
,7985513,Cmax1,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],38.55,134732,DB00367,Levonorgestrel
,7985513,Tp1,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),h,6,134733,DB00367,Levonorgestrel
,7985513,Tp1,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),h,4.67,134734,DB00367,Levonorgestrel
,7985513,Tp1,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),h,4.33,134735,DB00367,Levonorgestrel
,7985513,Ctrough,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],1.21,134736,DB00367,Levonorgestrel
,7985513,Ctrough,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],4.36,134737,DB00367,Levonorgestrel
,7985513,Ctrough,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],9.06,134738,DB00367,Levonorgestrel
,7985513,Ttrough,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,55,134739,DB00367,Levonorgestrel
,7985513,Ttrough,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,53.67,134740,DB00367,Levonorgestrel
,7985513,Ttrough,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,54.83,134741,DB00367,Levonorgestrel
,7985513,Cmax2,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],3.80,134742,DB00367,Levonorgestrel
,7985513,Cmax2,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],9.48,134743,DB00367,Levonorgestrel
,7985513,Cmax2,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[nM] / [l],19.68,134744,DB00367,Levonorgestrel
,7985513,Tp2,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,100.49,134745,DB00367,Levonorgestrel
,7985513,Tp2,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,102.21,134746,DB00367,Levonorgestrel
,7985513,Tp2,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,89.27,134747,DB00367,Levonorgestrel
,7985513,AUC,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[d·nM] / [l],440.27,134748,DB00367,Levonorgestrel
,7985513,AUC,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[d·nM] / [l],1082.82,134749,DB00367,Levonorgestrel
,7985513,AUC,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),[d·nM] / [l],1931.47,134750,DB00367,Levonorgestrel
,7985513,MRT,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,69.23,134751,DB00367,Levonorgestrel
,7985513,MRT,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,65.12,134752,DB00367,Levonorgestrel
,7985513,MRT,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,63.25,134753,DB00367,Levonorgestrel
<,7985513,T,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,0.32,134754,DB00367,Levonorgestrel
,7985513,T,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,167.81,134755,DB00367,Levonorgestrel
,7985513,T,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,169.73,134756,DB00367,Levonorgestrel
,7985513,T,"Cmax1 (the first phase) were 15.19, 33.61 and 38.55 nmol.L-1; Tp1 were 6, 4.67 and 4.33h; Ctrough were 1.21, 4.36 and 9.06 nmol.L-1; Ttrough were 55, 53.67 and 54.83 d; Cmax2 (the second phase) were 3.80, 9.48 and 19.68 nmol.L-1; Tp2 were 100.49, 102.21 and 89.27 d; AUC were 440.27, 1082.82 and 1931.47 nmol.d.L-1; MRT were 69.23, 65.12 and 63.25 d; T < 0.32 nmol.L-1 were 167.81, 169.73 and 167.23 d after im of LNG microspheres in doses of 20.4, 41.1 and 83.3 mg (LNG).",[Pharmacokinetics of levonorgestrel after a single dose of biodegradable microspheres containing levonorgestrel in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985513/),d,167.23,134757,DB00367,Levonorgestrel
,7921520,peak estradiol concentration,"Preliminary pharmacokinetic results obtained from 14 postmenopausal women being treated with the low-dose estrogen-progestogen replacement demonstrated peak estradiol concentration of 120-160 pmol/l (32-43 pg/ml) 10 hours after oral ingestion, suggesting bone preserving properties by these considerably lower estradiol concentrations.",Estrogen-progestogen replacement therapy in postmenopausal women--is 1 mg estradiolvalerate sufficient to maintain axial trabecular bone density? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7921520/),[pM] / [l],120-160,136709,DB00367,Levonorgestrel
,1458892,terminal half-life,"At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),h,24-26,140073,DB00367,Levonorgestrel
,1458892,terminal half-life,"At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),h,20,140074,DB00367,Levonorgestrel
,1458892,free fraction,"After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),%,1.3,140075,DB00367,Levonorgestrel
,1458892,fractions,"After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),%,64.1,140076,DB00367,Levonorgestrel
,1458892,fractions,"After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),%,34.6,140077,DB00367,Levonorgestrel
,1458892,AUC(0-24h),"On the last day of treatment cycles one and three, the AUC(0-24h) values of EE2 were 728 +/- 314 and 778 +/- 318 pg x ml-1 x h, respectively, and were in keeping with data reported from others.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),[h·pg] / [ml],728,140078,DB00367,Levonorgestrel
,1458892,AUC(0-24h),"On the last day of treatment cycles one and three, the AUC(0-24h) values of EE2 were 728 +/- 314 and 778 +/- 318 pg x ml-1 x h, respectively, and were in keeping with data reported from others.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),[h·pg] / [ml],778,140079,DB00367,Levonorgestrel
,1905949,Tel,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,17.3,142225,DB00367,Levonorgestrel
,1905949,Tel,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,16.4,142226,DB00367,Levonorgestrel
,1905949,AUC,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),[ng] / [h·ml],11.1,142227,DB00367,Levonorgestrel
,1905949,AUC,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,16.4,142228,DB00367,Levonorgestrel
,1905949,AUC,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),[ng] / [h·ml],12.5,142229,DB00367,Levonorgestrel
,1905949,Tel,"However, EE influenced the metabolism of LNG; Tel for LNG was 19.3 +/- 4.2 h when administered alone and significantly higher (30.0 +/- 11.2 h) when given with EE.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,19.3,142230,DB00367,Levonorgestrel
,1905949,Tel,"However, EE influenced the metabolism of LNG; Tel for LNG was 19.3 +/- 4.2 h when administered alone and significantly higher (30.0 +/- 11.2 h) when given with EE.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,30.0,142231,DB00367,Levonorgestrel
,3127114,fractional bioavailability,The fractional bioavailability of LNG after oral administration was 1.00 +/- 0.16 (mean +/- S.D.) and after vaginal insertion 0.88 +/- 0.16.,"Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,1.00,144138,DB00367,Levonorgestrel
,3127114,fractional bioavailability,The fractional bioavailability of LNG after oral administration was 1.00 +/- 0.16 (mean +/- S.D.) and after vaginal insertion 0.88 +/- 0.16.,"Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,0.88,144139,DB00367,Levonorgestrel
,3127114,fractional bioavailability,"The fractional bioavailability of EE2 after oral dosing was 0.62 +/- 0.11 and after vaginal insertion 0.74 +/- 0.16; tmax was prolonged, hence absorption was slower from the vagina.","Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,0.62,144140,DB00367,Levonorgestrel
,3127114,fractional bioavailability,"The fractional bioavailability of EE2 after oral dosing was 0.62 +/- 0.11 and after vaginal insertion 0.74 +/- 0.16; tmax was prolonged, hence absorption was slower from the vagina.","Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,0.74,144141,DB00367,Levonorgestrel
,3093146,number of bleeding days,"Only in two of the ten subjects did the average number of bleeding days per month increase from a pretreatment value of 4.5 days per month to 8.3 and 9.5 days per month, respectively.",Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093146/),[d] / [month],4.5,144434,DB00367,Levonorgestrel
,3093146,number of bleeding days,"Only in two of the ten subjects did the average number of bleeding days per month increase from a pretreatment value of 4.5 days per month to 8.3 and 9.5 days per month, respectively.",Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093146/),[d] / [month],8.3,144435,DB00367,Levonorgestrel
,3093146,number of bleeding days,"Only in two of the ten subjects did the average number of bleeding days per month increase from a pretreatment value of 4.5 days per month to 8.3 and 9.5 days per month, respectively.",Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093146/),[d] / [month],9.5,144436,DB00367,Levonorgestrel
,3121231,apparent clearance,The apparent clearance of levonorgestrel in group I was 80.9 +/- 15.6 ml/hr/kg and the half-life was 19.3 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),[ml] / [h·kg],80.9,147444,DB00367,Levonorgestrel
,3121231,half-life,The apparent clearance of levonorgestrel in group I was 80.9 +/- 15.6 ml/hr/kg and the half-life was 19.3 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),h,19.3,147445,DB00367,Levonorgestrel
,3121231,apparent oral clearance,The apparent oral clearance of ethinyl estradiol was 1002 +/- 398 ml/hr/kg in group I and the half-life averaged 7.7 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),[ml] / [h·kg],1002,147446,DB00367,Levonorgestrel
,3121231,half-life,The apparent oral clearance of ethinyl estradiol was 1002 +/- 398 ml/hr/kg in group I and the half-life averaged 7.7 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),h,7.7,147447,DB00367,Levonorgestrel
,29403692,maximum plasma concentration (Cmax),"After a Single intramuscular administration, the maximum plasma concentration (Cmax) was (289 ± 25) ng/mL, time to reach Cmax(tmax) was (0.38 ± 0.14) h, the elimination half-life (t1/2) was (2.5 ± 1.1) h, the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(0-t)) was (544 ± 73)ng · h/mL.",Pharmacokinetic behavior of 16-dehydropregnenolone after intramuscular administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403692/),[ng] / [ml],289,152156,DB00367,Levonorgestrel
,29403692,time to reach Cmax(tmax),"After a Single intramuscular administration, the maximum plasma concentration (Cmax) was (289 ± 25) ng/mL, time to reach Cmax(tmax) was (0.38 ± 0.14) h, the elimination half-life (t1/2) was (2.5 ± 1.1) h, the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(0-t)) was (544 ± 73)ng · h/mL.",Pharmacokinetic behavior of 16-dehydropregnenolone after intramuscular administration in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403692/),h,0.38,152157,DB00367,Levonorgestrel
,29403692,elimination half-life (t1/2),"After a Single intramuscular administration, the maximum plasma concentration (Cmax) was (289 ± 25) ng/mL, time to reach Cmax(tmax) was (0.38 ± 0.14) h, the elimination half-life (t1/2) was (2.5 ± 1.1) h, the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(0-t)) was (544 ± 73)ng · h/mL.",Pharmacokinetic behavior of 16-dehydropregnenolone after intramuscular administration in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403692/),h,2.5,152158,DB00367,Levonorgestrel
,29403692,area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(0-t)),"After a Single intramuscular administration, the maximum plasma concentration (Cmax) was (289 ± 25) ng/mL, time to reach Cmax(tmax) was (0.38 ± 0.14) h, the elimination half-life (t1/2) was (2.5 ± 1.1) h, the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC(0-t)) was (544 ± 73)ng · h/mL.",Pharmacokinetic behavior of 16-dehydropregnenolone after intramuscular administration in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403692/),[h·ng] / [ml],544,152159,DB00367,Levonorgestrel
,9089002,elimination half-lives,"The elimination half-lives of LNG did not differ between the test and reference preparations (25.08 +/- 11.94 h, and 25.70 +/- 10.08 h, respectively).",Bioavailability study with 2 different levonorgestrel-containing drugs in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089002/),h,25.08,163074,DB00367,Levonorgestrel
,9089002,elimination half-lives,"The elimination half-lives of LNG did not differ between the test and reference preparations (25.08 +/- 11.94 h, and 25.70 +/- 10.08 h, respectively).",Bioavailability study with 2 different levonorgestrel-containing drugs in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089002/),h,25.70,163075,DB00367,Levonorgestrel
,7547095,Cmax,"Only the ethinyloestradiol Cmax showed a significant difference (P = 0.02) between menstrual cycles 1 and 2 (252.9 pg ml-1 and 271.3 pg ml-1, respectively).",An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547095/),[pg] / [ml],252.9,163192,DB00367,Levonorgestrel
,7547095,Cmax,"Only the ethinyloestradiol Cmax showed a significant difference (P = 0.02) between menstrual cycles 1 and 2 (252.9 pg ml-1 and 271.3 pg ml-1, respectively).",An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547095/),[pg] / [ml],271.3,163193,DB00367,Levonorgestrel
,22536010,AUC(12),"With EFV, LNG AUC(12) was reduced 56% (95% CI: 49%, 62%) from 42.9 to 17.8 ng∗hr/mL, and maximum concentration (C(max)) was reduced 41% (95% CI: 33%, 50%) from 8.4 to 4.6 ng/mL.","Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536010/),[ng∗hr] / [ml],42,169127,DB00367,Levonorgestrel
,22536010,maximum concentration (C(max)),"With EFV, LNG AUC(12) was reduced 56% (95% CI: 49%, 62%) from 42.9 to 17.8 ng∗hr/mL, and maximum concentration (C(max)) was reduced 41% (95% CI: 33%, 50%) from 8.4 to 4.6 ng/mL.","Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22536010/),[ng] / [ml],8,169128,DB00367,Levonorgestrel
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],1.44,169553,DB00367,Levonorgestrel
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],0.82,169554,DB00367,Levonorgestrel
,22085058,"peak plasma concentration, C(max)","The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),[ng] / [ml],19.2,176441,DB00367,Levonorgestrel
,22085058,"peak plasma concentration, C(max)","The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),[ng] / [ml],3.21,176442,DB00367,Levonorgestrel
,22085058,"time, T(max)","The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),h,1.4,176443,DB00367,Levonorgestrel
,22085058,"time, T(max)","The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),h,6.6,176444,DB00367,Levonorgestrel
,22085058,AUC,"The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),[h·ng] / [ml],152.7,176445,DB00367,Levonorgestrel
,22085058,AUC,"The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),[h·ng] / [ml],52.5,176446,DB00367,Levonorgestrel
,22085058,half-life,"The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),h,25,176447,DB00367,Levonorgestrel
,22085058,half-life,"The oral or vaginal dose of 1.5 mg LNG resulted in peak plasma concentration, C(max) 19.2 or 3.21 ng/ml, with shorter time, T(max) 1.4 or 6.6 h, and greater AUC, 152.7 or 52.5 ng.h/ml, with shorter half-life, 25 or 32 h, respectively.","The emergency contraceptive drug, levonorgestrel: a review of post-coital oral and peri-coital vaginal administration for prevention of pregnancy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22085058/),h,32,176448,DB00367,Levonorgestrel
,1543818,percentage conjugation,The percentage conjugation per mg dry weight for normal tissue (n = 11) was 17.1 +/- 6.4 (mean +/- s.d.) while in untreated coeliac tissue (n = 6) the figure was 6.3 +/- 3.6% (P less than 0.01).,The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543818/),,17.1,177349,DB00367,Levonorgestrel
,1543818,percentage conjugation,The percentage conjugation per mg dry weight for normal tissue (n = 11) was 17.1 +/- 6.4 (mean +/- s.d.) while in untreated coeliac tissue (n = 6) the figure was 6.3 +/- 3.6% (P less than 0.01).,The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543818/),%,6.3,177350,DB00367,Levonorgestrel
,28087972,area under the plasma concentration-time curve over the dosing interval of duration τ,"LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration τ and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively.",Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087972/),,1.12,178605,DB00367,Levonorgestrel
,28087972,maximum observed plasma concentration,"LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration τ and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively.",Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087972/),,1.05,178606,DB00367,Levonorgestrel
below,1936077,t1/2,"Rat hepatocytes showed an extremely high metabolic activity towards NET, LN and GEST resulting in t1/2 values of below 2 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,2,181047,DB00367,Levonorgestrel
above,1936077,half-lives,"Respective values for rabbit hepatocytes ranged from 5-8 min, whereas half-lives calculated for liver cells from guinea pig, dog and monkey were generally above 30 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,30,181048,DB00367,Levonorgestrel
,29522253,maximum oral equivalent dose,"The maximum oral equivalent dose of ethinylestradiol was markedly lower than 30 μg ethinylestradiol per day (20.3 μg/day; 90% confidence interval, 14.8-28.0 μg/day).",In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522253/),[μg] / [d],20.3,183130,DB00367,Levonorgestrel
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],"1,778",185596,DB00367,Levonorgestrel
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],986,185597,DB00367,Levonorgestrel
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],24.8,185598,DB00367,Levonorgestrel
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],13.8,185599,DB00367,Levonorgestrel
,20472113,area under the curve (AUC,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[h·pg] / [ml],1077.2,188119,DB00367,Levonorgestrel
,20472113,area under the curve (AUC,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[h·pg] / [ml],1413.7,188120,DB00367,Levonorgestrel
,20472113,maximum values,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[pg] / [ml],85.7,188121,DB00367,Levonorgestrel
,20472113,maximum values,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[pg] / [ml],129.5,188122,DB00367,Levonorgestrel
,20472113,trough levels,"While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively).",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[ng] / [ml],2.6,188123,DB00367,Levonorgestrel
,20472113,trough levels,"While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively).",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[ng] / [ml],2.5,188124,DB00367,Levonorgestrel
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00367,Levonorgestrel
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],806,189197,DB00367,Levonorgestrel
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],411,189198,DB00367,Levonorgestrel
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189199,DB00367,Levonorgestrel
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189200,DB00367,Levonorgestrel
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189201,DB00367,Levonorgestrel
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189202,DB00367,Levonorgestrel
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],1163,189203,DB00367,Levonorgestrel
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],672,189204,DB00367,Levonorgestrel
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189205,DB00367,Levonorgestrel
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189206,DB00367,Levonorgestrel
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189207,DB00367,Levonorgestrel
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189208,DB00367,Levonorgestrel
,16009156,peak plasma concentrations (Cmax,"Compared with vaginal administration, oral administration resulted in higher peak plasma concentrations (Cmax 64 vs. 10.7 nmol/L), with a shorter time to reach the maximal concentrations (Tmax 1.4 vs. 6.6 hours) and with a greater AUC (509 vs. 175 nmol/L).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),[nM] / [l],64,189881,DB00367,Levonorgestrel
,16009156,peak plasma concentrations (Cmax,"Compared with vaginal administration, oral administration resulted in higher peak plasma concentrations (Cmax 64 vs. 10.7 nmol/L), with a shorter time to reach the maximal concentrations (Tmax 1.4 vs. 6.6 hours) and with a greater AUC (509 vs. 175 nmol/L).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),[nM] / [l],10.7,189882,DB00367,Levonorgestrel
,16009156,time to reach the maximal concentrations (Tmax,"Compared with vaginal administration, oral administration resulted in higher peak plasma concentrations (Cmax 64 vs. 10.7 nmol/L), with a shorter time to reach the maximal concentrations (Tmax 1.4 vs. 6.6 hours) and with a greater AUC (509 vs. 175 nmol/L).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),h,1.4,189883,DB00367,Levonorgestrel
,16009156,time to reach the maximal concentrations (Tmax,"Compared with vaginal administration, oral administration resulted in higher peak plasma concentrations (Cmax 64 vs. 10.7 nmol/L), with a shorter time to reach the maximal concentrations (Tmax 1.4 vs. 6.6 hours) and with a greater AUC (509 vs. 175 nmol/L).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),h,6.6,189884,DB00367,Levonorgestrel
,16009156,AUC,"Compared with vaginal administration, oral administration resulted in higher peak plasma concentrations (Cmax 64 vs. 10.7 nmol/L), with a shorter time to reach the maximal concentrations (Tmax 1.4 vs. 6.6 hours) and with a greater AUC (509 vs. 175 nmol/L).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),[nM] / [l],509,189885,DB00367,Levonorgestrel
,16009156,AUC,"Compared with vaginal administration, oral administration resulted in higher peak plasma concentrations (Cmax 64 vs. 10.7 nmol/L), with a shorter time to reach the maximal concentrations (Tmax 1.4 vs. 6.6 hours) and with a greater AUC (509 vs. 175 nmol/L).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),[nM] / [l],175,189886,DB00367,Levonorgestrel
,16009156,half-life,"Interestingly, the half-life of levonorgestrel was shorter after oral administration (25 hours vs. 32.6 hours).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),h,25,189887,DB00367,Levonorgestrel
,16009156,half-life,"Interestingly, the half-life of levonorgestrel was shorter after oral administration (25 hours vs. 32.6 hours).",Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal route. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16009156/),h,32.6,189888,DB00367,Levonorgestrel
>,33006493,bioavailability,Total LNG bioavailability was >97% for the LNG-IUSs and 66-80% with other contraceptives.,Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33006493/),%,97,190372,DB00367,Levonorgestrel
,33006493,bioavailability,Total LNG bioavailability was >97% for the LNG-IUSs and 66-80% with other contraceptives.,Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33006493/),%,66-80,190373,DB00367,Levonorgestrel
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB00367,Levonorgestrel
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB00367,Levonorgestrel
,3143516,half-life,It was found that the levonorgestrel decay rate after implant removal can be entirely accounted assuming one half-life of 42 +/- 16 h (mean +/- SD; range 13 to 62 h).,Clearance of levonorgestrel from the circulation following removal of NORPLANT subdermal implants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3143516/),h,42,198028,DB00367,Levonorgestrel
,18254150,ch,The method had a chromatographic running time of 2.0 min and linear calibration curves over the concentration ranges of 0.25-90 ng/mL for levonorgestrel.,Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254150/),min,2.0,198079,DB00367,Levonorgestrel
,18254150,running time,The method had a chromatographic running time of 2.0 min and linear calibration curves over the concentration ranges of 0.25-90 ng/mL for levonorgestrel.,Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254150/),min,2.0,198080,DB00367,Levonorgestrel
,18254150,running time,"These results indicate that the method was efficient with a simple preparation procedure and a very short running time (2.0 min) for levonorgestrel compared with those methods reported in the literature and had high selectivity, acceptable accuracy, precision and sensitivity.",Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254150/),min,2.0,198081,DB00367,Levonorgestrel
,27000996,Cmax,"The total LNG Cmax for obese subjects following ECx1 (5.57±2.48ng/mL) was significantly lower than the level observed in normal BMI women (10.30±2.47, p=.027).",Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27000996/),[ng] / [ml],5.57,200292,DB00367,Levonorgestrel
,27000996,Cmax,"The total LNG Cmax for obese subjects following ECx1 (5.57±2.48ng/mL) was significantly lower than the level observed in normal BMI women (10.30±2.47, p=.027).",Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27000996/),,10.30,200293,DB00367,Levonorgestrel
,25385099,t1/2 (terminal half-life in plasma at steady state,Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir.,Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385099/),h,2.4,203683,DB00367,Levonorgestrel
,25385099,t1/2 (terminal half-life in plasma at steady state,Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir.,Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385099/),h,4.7,203684,DB00367,Levonorgestrel
,15556549,recovery,"The mean recovery for levonorgestrel and 17-alpha-methyltestosterone was 99.5 and 62.9%, respectively.",Selective and sensitive liquid chromatography-tandem mass spectrometry method for the determination of levonorgestrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556549/),%,99.5,203995,DB00367,Levonorgestrel
,15556549,recovery,"The mean recovery for levonorgestrel and 17-alpha-methyltestosterone was 99.5 and 62.9%, respectively.",Selective and sensitive liquid chromatography-tandem mass spectrometry method for the determination of levonorgestrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556549/),%,62.9,203996,DB00367,Levonorgestrel
,15556549,total ch,"The total chromatographic runtime of this method was 5.0 min per sample, allowing for analysis of a large number of samples per batch.",Selective and sensitive liquid chromatography-tandem mass spectrometry method for the determination of levonorgestrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556549/),[min] / [sample],5.0,203997,DB00367,Levonorgestrel
,18969681,limits of detection (LOD),"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,6.7x10(-10),204048,DB00367,Levonorgestrel
,18969681,limits of detection (LOD),"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,2.2x10(-9),204049,DB00367,Levonorgestrel
,18969681,limits of detection (LOD),"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,4.8x10(-10),204050,DB00367,Levonorgestrel
,18969681,limits of detection (LOD),"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,1.6x10(-9),204051,DB00367,Levonorgestrel
,18969681,q,"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,6.7x10(-10),204052,DB00367,Levonorgestrel
,18969681,q,"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,2.2x10(-9),204053,DB00367,Levonorgestrel
,18969681,q,"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,4.8x10(-10),204054,DB00367,Levonorgestrel
,18969681,q,"The achieved limits of detection (LOD) and quantitation (LOQ) were 6.7x10(-10) and 2.2x10(-9)M, or 4.8x10(-10) and 1.6x10(-9)M, following accumulation onto the hanging mercury drop electrode for 90s or 150s, respectively.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),M,1.6x10(-9),204055,DB00367,Levonorgestrel
,18969681,C(max),"The pharmacokinetic parameters (C(max)=1.05ngml(-1), t(max)=2.4h and AUC(0-t)=16.5nghml(-1)) were estimated and favorably compared to those reported in literature for equivalent dose.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),1/[ngml],1.05,204056,DB00367,Levonorgestrel
,18969681,t(max),"The pharmacokinetic parameters (C(max)=1.05ngml(-1), t(max)=2.4h and AUC(0-t)=16.5nghml(-1)) were estimated and favorably compared to those reported in literature for equivalent dose.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),h,2.4,204057,DB00367,Levonorgestrel
,18969681,AUC(0-t),"The pharmacokinetic parameters (C(max)=1.05ngml(-1), t(max)=2.4h and AUC(0-t)=16.5nghml(-1)) were estimated and favorably compared to those reported in literature for equivalent dose.","Voltammetric behavior and assay of the contraceptive drug levonorgestrel in bulk, tablets, and human serum at a mercury electrode. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969681/),1/[nghml],16.5,204058,DB00367,Levonorgestrel
,23360419,AUC,"The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·pg] / [ml],"1,067",208129,DB00367,Levonorgestrel
,23360419,AUC,"The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·pg] / [ml],"1,173",208130,DB00367,Levonorgestrel
,23360419,Cmax,Corresponding values of Cmax were 116.9 ± 48.8 versus 135.7 ± 28.6 pg/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[pg] / [ml],116.9,208131,DB00367,Levonorgestrel
,23360419,Cmax,Corresponding values of Cmax were 116.9 ± 48.8 versus 135.7 ± 28.6 pg/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[pg] / [ml],135.7,208132,DB00367,Levonorgestrel
,23360419,AUC,"For levonorgestrel, the AUC alone was 74.2 ± 21.4 versus 80.9 ± 18.5 ng h/ml with lacosamide.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·ng] / [ml],74.2,208133,DB00367,Levonorgestrel
,23360419,AUC,"For levonorgestrel, the AUC alone was 74.2 ± 21.4 versus 80.9 ± 18.5 ng h/ml with lacosamide.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·ng] / [ml],80.9,208134,DB00367,Levonorgestrel
,23360419,Cmax,Corresponding values of Cmax were 6.7 ± 1.9 versus 7.4 ± 1.5 ng/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[ng] / [ml],6.7,208135,DB00367,Levonorgestrel
,23360419,Cmax,Corresponding values of Cmax were 6.7 ± 1.9 versus 7.4 ± 1.5 ng/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[ng] / [ml],7.4,208136,DB00367,Levonorgestrel
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.5,208137,DB00367,Levonorgestrel
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.4,208138,DB00367,Levonorgestrel
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.5,208139,DB00367,Levonorgestrel
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.1,208140,DB00367,Levonorgestrel
,23360419,AUC,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·μg] / [ml],113.5,208141,DB00367,Levonorgestrel
,23360419,Cmax,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[μg] / [ml],13.8,208142,DB00367,Levonorgestrel
,23360419,tmax,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.1,208143,DB00367,Levonorgestrel
,3082591,bioavailability,The mean bioavailability of ethinyloestradiol in the patients with an ileostomy was 55.4 +/- 10.9% (+/- S.D.) compared to a control value of 45.0 +/- 6.1% (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,55.4,208972,DB00367,Levonorgestrel
,3082591,bioavailability,The mean bioavailability of ethinyloestradiol in the patients with an ileostomy was 55.4 +/- 10.9% (+/- S.D.) compared to a control value of 45.0 +/- 6.1% (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,45.0,208973,DB00367,Levonorgestrel
,3082591,bioavailability,The mean bioavailability of levonorgestrel in the ileostomy patients was 85.2 +/- 13.1% compared to 104.6 +/- 22.3% in the controls (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,85.2,208974,DB00367,Levonorgestrel
,3082591,bioavailability,The mean bioavailability of levonorgestrel in the ileostomy patients was 85.2 +/- 13.1% compared to 104.6 +/- 22.3% in the controls (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,104.6,208975,DB00367,Levonorgestrel
,25070547,time to reach steady state,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),d,12,213784,DB00367,Levonorgestrel
,25070547,Cmax,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[ng] / [ml],3.82,213785,DB00367,Levonorgestrel
,25070547,Cmax,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[ng] / [ml],3.13,213786,DB00367,Levonorgestrel
,25070547,AUC0-∞,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],267,213787,DB00367,Levonorgestrel
,25070547,AUC0-∞,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],199,213788,DB00367,Levonorgestrel
,25070547,AUC,"However, AUC was not significantly different between CC (412±255 h ng/mL) and ID (283±130 h ng/mL).",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],412,213789,DB00367,Levonorgestrel
,25070547,AUC,"However, AUC was not significantly different between CC (412±255 h ng/mL) and ID (283±130 h ng/mL).",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],283,213790,DB00367,Levonorgestrel
,17364874,relative bioavailabilities,The relative bioavailabilities of these liposome formulations via nasal administration were 100% or higher than 100%.,Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),%,100,216773,DB00367,Levonorgestrel
higher,17364874,relative bioavailabilities,The relative bioavailabilities of these liposome formulations via nasal administration were 100% or higher than 100%.,Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),%,100,216774,DB00367,Levonorgestrel
,17364874,Cmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),[ng] / [ml],416.84,216775,DB00367,Levonorgestrel
,17364874,Cmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),h,1.02,216776,DB00367,Levonorgestrel
,17364874,Cmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),[ng] / [ml],227.97,216777,DB00367,Levonorgestrel
,17364874,Cmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),[ng] / [ml],334.94,216778,DB00367,Levonorgestrel
,17364874,Tmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),h,1.02,216779,DB00367,Levonorgestrel
,17364874,Tmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),h,2.02,216780,DB00367,Levonorgestrel
,17364874,Tmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),[ng] / [ml],334.94,216781,DB00367,Levonorgestrel
,17364874,Tmax,"The Cmax and Tmax values of sterylglucoside (SG) and chitosan-contained formulations by nasal administration were 416.84 ng/mL and 1.02 hr, 227.97 ng/mL and 2.02 hr, respectively, compared with that of 334.94 ng/mL and 1.89 hr of oral suspension.",Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17364874/),h,1.89,216782,DB00367,Levonorgestrel
,12169384,peak plasma LNG concentration,The observed mean peak plasma LNG concentration was 14.1 +/- 7.9 ng/mL (range 6.7-39.0 ng/mL).,Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),[ng] / [ml],14.1,217193,DB00367,Levonorgestrel
,12169384,time of peak concentration,The mean time of peak concentration was 1.63 +/- 0.74 h (range 1-4 h).,Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),h,1.63,217194,DB00367,Levonorgestrel
,12169384,Half-lives,Half-lives calculated from the terminal decline in plasma LNG concentrations ranged from 16.2 h to 32.3 h (mean = 24.4 +/- 5.3 h).,Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),h,16.2,217195,DB00367,Levonorgestrel
,12169384,Half-lives,Half-lives calculated from the terminal decline in plasma LNG concentrations ranged from 16.2 h to 32.3 h (mean = 24.4 +/- 5.3 h).,Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),h,32.3,217196,DB00367,Levonorgestrel
,12169384,Half-lives,Half-lives calculated from the terminal decline in plasma LNG concentrations ranged from 16.2 h to 32.3 h (mean = 24.4 +/- 5.3 h).,Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),h,24.4,217197,DB00367,Levonorgestrel
,12169384,Cl/F,"The Cl/F was 7.06 +/- 2.69 L/h, V/F was 260 +/- 129 L, and MRT was 27.8 +/- 5.2 h.",Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),[l] / [h],7.06,217198,DB00367,Levonorgestrel
,12169384,V/F,"The Cl/F was 7.06 +/- 2.69 L/h, V/F was 260 +/- 129 L, and MRT was 27.8 +/- 5.2 h.",Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),l,260,217199,DB00367,Levonorgestrel
,12169384,MRT,"The Cl/F was 7.06 +/- 2.69 L/h, V/F was 260 +/- 129 L, and MRT was 27.8 +/- 5.2 h.",Pharmacokinetics of levonorgestrel 0.75 mg tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169384/),h,27.8,217200,DB00367,Levonorgestrel
,19631786,half-life,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),h,52.1,218919,DB00367,Levonorgestrel
,19631786,half-life,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),h,25.6,218920,DB00367,Levonorgestrel
,19631786,maximum LNG concentration,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),[ng] / [ml],1.9,218921,DB00367,Levonorgestrel
,19631786,maximum LNG concentration,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),[ng] / [ml],2.5,218922,DB00367,Levonorgestrel
,19631786,time to reach steady state,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),d,10,218923,DB00367,Levonorgestrel
,19631786,time to reach steady state,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),d,5,218924,DB00367,Levonorgestrel
,24310360,m/z,The protonated precursor to product ion transitions monitored for norgestrel and IS were at m/z 313.30→245.40 and 319.00→251.30 respectively.,"A simple, rapid and sensitive UFLC-MS/MS method for the quantification of oral contraceptive norgestrel in human plasma and its pharmacokinetic applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24310360/),,313.30,221028,DB00367,Levonorgestrel
,24310360,m/z,The protonated precursor to product ion transitions monitored for norgestrel and IS were at m/z 313.30→245.40 and 319.00→251.30 respectively.,"A simple, rapid and sensitive UFLC-MS/MS method for the quantification of oral contraceptive norgestrel in human plasma and its pharmacokinetic applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24310360/),,319.00,221029,DB00367,Levonorgestrel
,24310360,run time,The method was validated with a linearity range of 304.356-50 807.337 pg/mL having run time of 2.0 min per sample.,"A simple, rapid and sensitive UFLC-MS/MS method for the quantification of oral contraceptive norgestrel in human plasma and its pharmacokinetic applications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24310360/),[min] / [sample],2.0,221030,DB00367,Levonorgestrel
,2959449,Bioavailability,Bioavailability ranged between 40.0 and 113% with a mean value ( +/- SD) of 76.1 +/- 22.5%.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),%,40.0 and 113,226075,DB00367,Levonorgestrel
,2959449,Bioavailability,Bioavailability ranged between 40.0 and 113% with a mean value ( +/- SD) of 76.1 +/- 22.5%.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),%,76.1,226076,DB00367,Levonorgestrel
less,2959449,bioavailability,Only 3 subjects had a bioavailability of less than 70%.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),%,70,226077,DB00367,Levonorgestrel
,2959449,elimination half life,There was no significant difference in the elimination half life of 3-keto-desogestrel which was 12.6 +/- 4.1h following i.v. administration and 11.9 +/- 4.1h after oral administration of desogestrel.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),h,12.6,226078,DB00367,Levonorgestrel
,2959449,elimination half life,There was no significant difference in the elimination half life of 3-keto-desogestrel which was 12.6 +/- 4.1h following i.v. administration and 11.9 +/- 4.1h after oral administration of desogestrel.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),h,11.9,226079,DB00367,Levonorgestrel
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,13.8,233249,DB00367,Levonorgestrel
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,13.3,233250,DB00367,Levonorgestrel
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,25.9,233251,DB00367,Levonorgestrel
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,25.4,233252,DB00367,Levonorgestrel
,22133660,maximum serum concentration (C(max)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],51.3,239964,DB00367,Levonorgestrel
,22133660,area under the curve(0-168 h),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[h·ng] / [ml],6.26,239965,DB00367,Levonorgestrel
,22133660,area under the curve(0-168 h),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],2400,239966,DB00367,Levonorgestrel
,22133660,area under the curve(0-168 h),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[h·ng] / [ml],317,239967,DB00367,Levonorgestrel
,22133660,steady-state concentration (C(ss48-168 h)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],35.7,239968,DB00367,Levonorgestrel
,22133660,steady-state concentration (C(ss48-168 h)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[h·ng] / [ml],317,239969,DB00367,Levonorgestrel
,22133660,steady-state concentration (C(ss48-168 h)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],1847,239970,DB00367,Levonorgestrel
,3087697,peak level,The plasma LNOG levels were found to reach a peak level ranging from 2.7-7.5 ng/ml within 4 days after the IVR insertion.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[ng] / [ml],2.7-7.5,241883,DB00367,Levonorgestrel
,3087697,release rates,The range of release rates calculated from plasma steady-state values was 51-119 micrograms/day.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],51-119,241884,DB00367,Levonorgestrel
,3087697,release rates,The average release rates over the entire period of observation based on area under curve were 102-200 micrograms/day.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],102-200,241885,DB00367,Levonorgestrel
,3087697,area under curve,The average release rates over the entire period of observation based on area under curve were 102-200 micrograms/day.,Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],102-200,241886,DB00367,Levonorgestrel
,3087697,release rates,"On the other hand, the release rates obtained from the residual drug in the ring after a period of use ranged from 184-259 micrograms/day.",Bioavailability of levonorgestrel from intravaginal rings in women of low income groups. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3087697/),[μg] / [d],184-259,241887,DB00367,Levonorgestrel
,32494773,overall pregnancy rate,"The overall pregnancy rate for the third, fourth and fifth years of product use was 0.63 per 100 WY; 95% CI: (0.17-1.62).","Cohort study to evaluate efficacy, safety and acceptability of a two-rod contraceptive implant during third, fourth and fifth year of product use in China. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32494773/),1/[100·wy],0.63,242354,DB00367,Levonorgestrel
less,32494773,Pearl Index,"Sino-implant (II) is a highly effective contraceptive method with an estimated Pearl Index of less than 1% over the third, fourth and fifth years of use in a population of Chinese women of reproductive age.","Cohort study to evaluate efficacy, safety and acceptability of a two-rod contraceptive implant during third, fourth and fifth year of product use in China. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32494773/),%,1,242355,DB00367,Levonorgestrel
,6434231,half-lives,"The half-lives for the alpha, beta and gamma phases were 10.1 min, 42.7 min and 23.1 hours, respectively.",Pharmacokinetics of levonorgestrel in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434231/),min,10.1,243748,DB00367,Levonorgestrel
,6434231,half-lives,"The half-lives for the alpha, beta and gamma phases were 10.1 min, 42.7 min and 23.1 hours, respectively.",Pharmacokinetics of levonorgestrel in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434231/),min,42.7,243749,DB00367,Levonorgestrel
,6434231,half-lives,"The half-lives for the alpha, beta and gamma phases were 10.1 min, 42.7 min and 23.1 hours, respectively.",Pharmacokinetics of levonorgestrel in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434231/),h,23.1,243750,DB00367,Levonorgestrel
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],3.0 to 6.0,244163,DB00367,Levonorgestrel
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.4 to 13.4,244164,DB00367,Levonorgestrel
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],38.2 to 88.3,244165,DB00367,Levonorgestrel
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],88.3 to 217.2,244166,DB00367,Levonorgestrel
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],5.2 to 1.5,244167,DB00367,Levonorgestrel
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.8 to 1.9,244168,DB00367,Levonorgestrel
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],62.4 to 14.4,244169,DB00367,Levonorgestrel
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],87.8 to 19.6,244170,DB00367,Levonorgestrel
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·pg] / [ml],1,245147,DB00367,Levonorgestrel
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·ng] / [ml],137,245148,DB00367,Levonorgestrel
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],180,245149,DB00367,Levonorgestrel
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],117,245150,DB00367,Levonorgestrel
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],10.2,245151,DB00367,Levonorgestrel
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],7.7,245152,DB00367,Levonorgestrel
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,13,245153,DB00367,Levonorgestrel
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,28.8,245154,DB00367,Levonorgestrel
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,15,245155,DB00367,Levonorgestrel
,24682015,flow rate,"Metapristone in plasma was recovered by liquid-liquid extraction using 1 mL of ethyl acetate and chromatographic separation was carried on a C₁₈ column at 35 °C, with a gradient mobile phase consisting of methanol and water containing 0.1% (v/v) formic acid at a flow rate of 0.3 mL/min.","A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24682015/),[ml] / [min],0.3,252025,DB00367,Levonorgestrel
,24682015,m/z,Multiple reaction monitoring was used for quantitation of m/z transitions from 416.3 to 119.9 for metapristone and from 313.1 to 109 for levonorgestrel (internal standard).,"A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24682015/),,41,252026,DB00367,Levonorgestrel
,24682015,m/z,Multiple reaction monitoring was used for quantitation of m/z transitions from 416.3 to 119.9 for metapristone and from 313.1 to 109 for levonorgestrel (internal standard).,"A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24682015/),,313.1 to 109,252027,DB00367,Levonorgestrel
,19882745,flow rate,The flow rate and detection wavelength were 1.0 mL/min and 230 nm.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),[ml] / [min],1.0,259927,DB00367,Levonorgestrel
,19882745,detection wavelength,The flow rate and detection wavelength were 1.0 mL/min and 230 nm.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),,230,259928,DB00367,Levonorgestrel
,19882745,limits of detection,"The correlation coefficients were greater than 0.9995 within 0.08-50 microg/mL for levonorgestrel and 0.12-50 microg/mL for quinestrol, and the limits of detection were 0.02 and 0.05 microg/mL for levonorgestrel and quinestrol, respectively.",Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),[μg] / [ml],0.02,259929,DB00367,Levonorgestrel
,19882745,limits of detection,"The correlation coefficients were greater than 0.9995 within 0.08-50 microg/mL for levonorgestrel and 0.12-50 microg/mL for quinestrol, and the limits of detection were 0.02 and 0.05 microg/mL for levonorgestrel and quinestrol, respectively.",Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),[μg] / [ml],0.05,259930,DB00367,Levonorgestrel
,19882745,recovery,Average recovery ranged from 92.5 to 96.3% and inter-day RSDs were less than 7.56%.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),%,92.5 to 96.3,259931,DB00367,Levonorgestrel
less,19882745,RSDs,Average recovery ranged from 92.5 to 96.3% and inter-day RSDs were less than 7.56%.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),,7,259932,DB00367,Levonorgestrel
,30703352,Cmax,"After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],10.5,259967,DB00367,Levonorgestrel
,30703352,Cmax,"After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],16.2,259968,DB00367,Levonorgestrel
,30703352,AUC,"After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],208,259969,DB00367,Levonorgestrel
,30703352,AUC,"After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],197,259970,DB00367,Levonorgestrel
,30703352,AUC,"After LNG-EC, mean total LNG metrics were lower in the obese and extremely obese groups compared to normal (Cmax 10.5 and 10.5 versus 16.2 ng/mL, both p<.01; AUC 208 and 197 versus 360 h × ng/mL, both p<.05).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],360,259971,DB00367,Levonorgestrel
,30703352,bioavailable,"Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],7.03,259972,DB00367,Levonorgestrel
,30703352,bioavailable,"Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],7.53,259973,DB00367,Levonorgestrel
,30703352,bioavailable,"Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],9.39,259974,DB00367,Levonorgestrel
,30703352,Cmax,"Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],7.03,259975,DB00367,Levonorgestrel
,30703352,Cmax,"Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],7.53,259976,DB00367,Levonorgestrel
,30703352,Cmax,"Mean bioavailable LNG Cmax was lower in obese (7.03 ng/mL, p<.05) and extremely obese (7.53 ng/ml, p=.198) compared to normal BMI (9.39 ng/mL).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[ng] / [ml],9.39,259977,DB00367,Levonorgestrel
,30703352,bioavailable LNG,"Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],131.6,259978,DB00367,Levonorgestrel
,30703352,bioavailable LNG,"Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],127.5,259979,DB00367,Levonorgestrel
,30703352,bioavailable LNG,"Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],185.0,259980,DB00367,Levonorgestrel
,30703352,AUC,"Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],131.6,259981,DB00367,Levonorgestrel
,30703352,AUC,"Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],127.5,259982,DB00367,Levonorgestrel
,30703352,AUC,"Mean bioavailable LNG AUC values were lower in obese and extremely obese compared to normal (131.6 and 127.5 vs 185.0 h × ng/mL, p<.05 for both).","Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30703352/),[h·ng] / [ml],185.0,259983,DB00367,Levonorgestrel
at,2516312,shelf-life,"Judging from the 6-month accelerated stability studies, it is projected these two formulations will have shelf-life of at least 2 years.","Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516312/),years,2,261886,DB00367,Levonorgestrel
,10771454,tmax,The tmax for levonorgestrel was approximately 0.5 h longer.,Ziprasidone and the pharmacokinetics of a combined oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771454/),h,0.5,267673,DB00367,Levonorgestrel
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],880,269574,DB00367,Levonorgestrel
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.1,269575,DB00367,Levonorgestrel
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],977,269576,DB00367,Levonorgestrel
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.2,269577,DB00367,Levonorgestrel
,23228503,time to maximum drug concentration (Tmax,"For plasma EE levels, median time to maximum drug concentration (Tmax, 24-48 h) and mean maximum concentration (Cmax, 47.9-61.5 pg/mL) were similar among application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),h,24-48,270278,DB00367,Levonorgestrel
,23228503,maximum concentration (Cmax,"For plasma EE levels, median time to maximum drug concentration (Tmax, 24-48 h) and mean maximum concentration (Cmax, 47.9-61.5 pg/mL) were similar among application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),[pg] / [ml],47.9-61.5,270279,DB00367,Levonorgestrel
,23228503,Tmax,"For plasma LNG levels, median Tmax (72-120 h) and mean Cmax (1436-1589 pg/mL) were similar across application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),h,72-120,270280,DB00367,Levonorgestrel
,23228503,Cmax,"For plasma LNG levels, median Tmax (72-120 h) and mean Cmax (1436-1589 pg/mL) were similar across application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),[pg] / [ml],1436-1589,270281,DB00367,Levonorgestrel
,17258945,run time,"The LC run time is at least 6 min, enabling analysis of only about 100 samples a day.",A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258945/),min,6,271149,DB00367,Levonorgestrel
,17258945,run time,In the present work the throughput was greatly improved by employing a semi-automated sample preparation process involving liquid-liquid extraction and derivatization with dansyl chloride followed by UPLC separation on a small particle size column achieving a run time of 2.7 min.,A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258945/),min,2.7,271150,DB00367,Levonorgestrel
